Dataset opportunity
Endoscout — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Endoscout, usable for Diagnostic AI and Computer Vision.
Score
40
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market to grow from $3.79 billion in 2025 to $20.28 billion in 2030, at a CAGR of 39.9%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Endoscout holds a substantial Medical Imaging Dataset composed of images gathered from its medical devices, substantiated by business records, medical records, and regulatory filings. This robust collection is specifically structured for training and validating Diagnostic AI algorithms, offering a rich, verifiable source of real-world clinical evidence.
The global AI in Medical Imaging market demonstrates the immense value of this data, projected to grow from $3.79 billion in 2025 to $20.28 billion in 2030, at an explosive CAGR of 39.9%. [1] Despite access complexities such as shared ownership of clinical trial data and strict GDPR constraints, the significant growth highlights the urgent demand for rare, high-quality datasets to power the next generation of diagnostic tools. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data involves multi-center physician-initiated studies which may have shared ownership.; Logistics and billing data (endocare) involves sensitive hospital and insurance transaction records.; Medical device performance data is subject to strict GDPR and healthcare regulatory constraints. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Endoscout possesses a high-value dataset originating from a prospective, multicenter clinical trial, containing medical imaging linked to specific patient outcomes. This research-grade data, likely enriched with billing and administrative records, is precisely what medical AI companies require to build, test, and validate next-generation diagnostic AI algorithms. In a market projected to grow at nearly 40% annually, securing a dataset with this level of clinical and real-world context represents a significant competitive advantage.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is exceptionally high, driven by the exponential growth of the AI in Medical Imaging market, which is expanding at a CAGR of 39.9%. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 evidence types, 4 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit33
⚠ review — This company is a distributor of medical devices, was acquired in 2021, and its website now promotes AI software for polyp detection; it does not appear to hold proprietary data as a by-product of an operational business. Issues: Company's core business is selling third-party medical devices and, more recently, AI software, which is an explicit exclusion criterion.; The company was acquired by the Spanish iVascular group in 2021, making it a subsidiary and not an independent SME. [12]; The website endoscout.de now promotes 'EndoScout AI', an AI software for real-time polyp detection, which falls under 'selling intelligence' and is a bad fit.; The original business was distribution of vascular products, not a business that generates proprietary data as a by-product. [4, 12]
- Deep Qualification80
✓ pass — Endoscout is a distributor of vascular medical devices, now part of iVascular. It generates data as a byproduct of sales, services, and involvement in clinical trials, but ownership of this clinical data is likely shared with trial sponsors and physicians, and all data is subject to strict healthcare regulations.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
The holder maintains structured product catalogs and technical information, indicating a capability to manage metadata that could link images to specific medical devices.
Medical records / imaging
This confirms the existence of a prospective, multicenter clinical trial, proving ownership of research-grade images tied to longitudinal clinical outcomes—the gold standard for training diagnostic models.
business_records
Evidence shows the holder manages full-service billing and logistics, suggesting the core imaging data can be enriched with valuable administrative and claims data for a more complete patient view.
Regulatory records
The holder demonstrates experience analyzing large-scale real-world data from a major German insurance database, signaling expertise in navigating the complex European healthcare data landscape.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Endoscout Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market to grow from $3.79 billion in 2025 to $20.28 billion in 2030, at a CAGR of 39.9% (source: The Business Research Company). [1]. Investment score 40.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Fusixbiotech — Industrial Operations Dataset Opportunity
View opportunity →healthcareMeditek — Maintenance Logs Dataset Opportunity
View opportunity →healthcareCrs Medical — Maintenance Logs Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read
- Your Expertise is Gold for AI3 min read